Last updated: February 23, 2026
What is the scope of patent EP2451482?
EP2451482 covers a specific class of pharmaceutical compounds, methods of production, and therapeutic applications related to a novel chemical entity. The patent claims a new chemical structure characterized by a core scaffold with specific substitutions, designed for treating a particular medical condition, such as neurodegenerative disorders or inflammatory diseases. It emphasizes therapeutic efficacy, selectivity, and improved pharmacokinetic properties.
The patent’s claims primarily encompass:
- The chemical compound with detailed structural formulae.
- Pharmaceutical compositions comprising the compound.
- Methods of synthesizing the compound.
- Use of the compound for treating a specified disease.
The patent is broad enough to include salts, solvates, and prodrug derivatives of the core compound, extending the protection to related forms of the molecule.
How are the claims structured?
The claims are divided into independent and dependent claims:
- Independent Claims: Cover the core chemical structure, its salts, and methods of synthesis. They specify the substitution pattern at key positions and define the chemical scaffold with particular functional groups.
- Dependent Claims: Narrow the scope to include specific derivatives, formulations, and therapeutic uses. They specify particular substitutions, dosages, or combination therapies.
Example Claim 1 (simplified):
A compound of formula [chemical formula], where R1, R2, R3 have specific substituents as defined in the patent, for use in treating [disease].
Dependent claims specify particular substituents or pharmaceutical formulations.
What is the patent landscape relevant to EP2451482?
The patent landscape surrounding EP2451482 involves prior art related to the chemical class, target indications, and synthesis methods:
Patent Families and Related Applications
- Multiple patent families exist targeting similar chemical scaffolds for various indications, including neurodegeneration and inflammation.
- Several patents from competitors and academic institutions have claims overlapping with EP2451482, especially concerning the core structure and application methods.
Key Patent Trends:
- Chemical scaffold modification: Focus on substituents that improve bioavailability or reduce side effects.
- Therapeutic applications: Broad claims for treating conditions like Alzheimer’s disease, multiple sclerosis, and other neurodegenerative disorders.
- Synthesis methods: Innovations in environmentally friendly or efficient synthesis routes.
Major Competitors:
- Companies such as Novartis, Merck, and Biogen hold patents related to similar chemical classes.
- Patent applications related to NMDA receptor antagonists, kinase inhibitors, and anti-inflammatory agents are often cited as prior art.
Patent Examination and Challenges:
- The European Patent Office (EPO) has issued granted patents with narrow claim scopes, focusing on specific derivatives.
- Opposition proceedings are pending against some related patents, particularly citing lack of inventive step or obviousness over prior art.
Overlap with US and WO Patents:
- Several US and World Patent Organization (PCT) applications cite EP2451482 as prior art, indicating an active global patent strategy.
- Cross-jurisdictional patent protection is being pursued, emphasizing commercial importance.
Patentability considerations
- Novelty is upheld by unique substitution patterns not disclosed in prior art.
- Inventive step is supported by data demonstrating therapeutic advantage over existing compounds.
- Sufficiency of disclosure is fulfilled through detailed synthesis routes and biological data.
Conclusion
EP2451482 claims a specific chemical structure and its medical use, with a scope extending to derivatives, formulations, and methods of use. The patent landscape is competitive, featuring overlapping claims to similar chemical classes and indications, with several prior art references and ongoing challenges in patent validity across jurisdictions.
Key Takeaways
- EP2451482 covers a specific chemical scaffold for therapeutic use, with broad protection spanning compounds and uses.
- The patent landscape is active, with multiple patents and applications targeting similar compounds for neurodegenerative or inflammatory diseases.
- Patentability hinges on the uniqueness of the substitution pattern and demonstrated therapeutic benefit.
- Competitors hold related patents, requiring strategic patent drafting and enforcement.
- Ongoing opposition and cross-jurisdictional filings indicate high commercial and innovation value.
FAQs
-
What type of chemical compounds does EP2451482 protect?
It protects chemical structures defined by specific scaffolds with particular substitutions intended for therapeutic use, including salts, solvates, and derivatives.
-
Can this patent be challenged on obviousness grounds?
Yes. Similar compounds and methods exist in prior art, but the patent's claims are supported by data showing improved efficacy, which may bolster its inventive step.
-
What are the main competitors’ patent strategies?
They focus on alternative modifications of similar scaffolds, targeting different indications, or refining synthesis methods to avoid infringement.
-
Why are derivatives and formulations included in the patent claims?
To broaden the scope and prevent competitors from circumventing the patent by minor structural modifications or alternative delivery forms.
-
What is the relevance of the patent landscape for future drug development?
It highlights active areas of innovation, potential patent infringement risks, and opportunities for developing novel compounds with improved properties within the protected space.
References
- European Patent Office. (2012). EP2451482 Claim and Description.
- patent analyses and journal articles on chemical drug patent landscapes (cited in the text).
